Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study

Brief description of study

The purpose of the trial is to determine the safety and efficacy of the standard treatment for children diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and Down Syndrome (DS). The study will use response-based treatment and participants will be separated into two different risk groups based on their response to the first stage of treatment. The study team want to know if participants with high risk of Myeloid Leukemia of Down Syndrome (AML and MDS in Down syndrome) can be successfully treated with stronger chemotherapy.

Clinical Study Identifier: s19-00277
ClinicalTrials.gov Identifier: NCT02521493
Principal Investigator: Chana Glasser.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.